We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AFMD
2876
DELISTED
Affimed
AFMD
$38K ﹤0.01%
1,357
+320
+31% +$11K
NAT icon
2877
Nordic American Tanker
NAT
$1.41B
$38K ﹤0.01%
17,886
+2,822
+19% +$6.74K
SLS icon
2878
SELLAS Life Sciences
SLS
$2.4B
$38K ﹤0.01%
17,100
NAGE
2879
Niagen Bioscience
NAGE
$240M
$38K ﹤0.01%
22,500
-30,772
-58% -$60.2K
VRAY
2880
DELISTED
ViewRay, Inc.
VRAY
$38K ﹤0.01%
14,313
+1,000
+8% +$3.01K
ACHR icon
2881
Archer Aviation
ACHR
$5.04B
$37K ﹤0.01%
+11,880
New +$47.8K
ATOS icon
2882
Atossa Therapeutics
ATOS
$24.2M
$37K ﹤0.01%
2,293
-683
-23% -$10.8K
STIM icon
2883
Neuronetics
STIM
$228M
$37K ﹤0.01%
11,500
-2,313
-17% -$6.71K
SRT
2884
DELISTED
Startek Inc.
SRT
$37K ﹤0.01%
12,800
-1,517
-11% -$5.62K
ADMA icon
2885
ADMA Biologics
ADMA
$2.11B
$35K ﹤0.01%
+17,734
New +$34.9K
SVRA icon
2886
Savara
SVRA
$1.11B
$35K ﹤0.01%
22,760
+900
+4% +$1.18K
AIOT
2887
PowerFleet Inc
AIOT
$416M
$35K ﹤0.01%
15,900
DS
2888
DELISTED
Drive Shack Inc.
DS
$35K ﹤0.01%
25,350
-8,486
-25% -$12.1K
CLSD
2889
DELISTED
Clearside Biomedical
CLSD
$34K ﹤0.01%
1,547
MLSS icon
2890
Milestone Scientific
MLSS
$47.8M
$34K ﹤0.01%
36,700
IMDX
2891
Insight Molecular Diagnostics
IMDX
$137M
$33K ﹤0.01%
1,830
-249
-12% -$5.66K
RLX icon
2892
RLX Technology
RLX
$2.47B
$33K ﹤0.01%
15,500
STXS icon
2893
Stereotaxis
STXS
$138M
$33K ﹤0.01%
17,800
-4,576
-20% -$10.9K
HLTH
2894
DELISTED
Cue Health Inc. Common Stock
HLTH
$33K ﹤0.01%
10,283
-142,102
-93% -$770K
SPPI
2895
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$32K ﹤0.01%
40,948
-14,078
-26% -$12.4K
LHDX
2896
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$32K ﹤0.01%
17,400
TIO
2897
DELISTED
Tingo Group, Inc. Common Stock
TIO
$32K ﹤0.01%
55,400
CORZ
2898
DELISTED
Core Scientific, Inc. Common Stock
CORZ
$31K ﹤0.01%
+20,882
New +$96K
UP icon
2899
Wheels Up
UP
$186M
$30K ﹤0.01%
+76
New +$40.6K
RNAC icon
2900
Cartesian Therapeutics
RNAC
$267M
$29K ﹤0.01%
727
+149
+26% +$4.42K

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.